CA3151909A1 - Therapeutic or prophylactic method for diabetes using combination medicine - Google Patents
Therapeutic or prophylactic method for diabetes using combination medicine Download PDFInfo
- Publication number
- CA3151909A1 CA3151909A1 CA3151909A CA3151909A CA3151909A1 CA 3151909 A1 CA3151909 A1 CA 3151909A1 CA 3151909 A CA3151909 A CA 3151909A CA 3151909 A CA3151909 A CA 3151909A CA 3151909 A1 CA3151909 A1 CA 3151909A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- date received
- date recue
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019161526 | 2019-09-04 | ||
JP2019-161526 | 2019-09-04 | ||
PCT/JP2020/033463 WO2021045159A1 (ja) | 2019-09-04 | 2020-09-03 | 併用医薬による糖尿病の治療又は予防方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3151909A1 true CA3151909A1 (en) | 2021-03-11 |
Family
ID=74852211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3151909A Pending CA3151909A1 (en) | 2019-09-04 | 2020-09-03 | Therapeutic or prophylactic method for diabetes using combination medicine |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230119894A1 (ja) |
EP (2) | EP4026564A4 (ja) |
JP (1) | JPWO2021045159A1 (ja) |
KR (1) | KR20220056219A (ja) |
CN (1) | CN114585387A (ja) |
AU (1) | AU2020341926A1 (ja) |
BR (1) | BR112022003323A2 (ja) |
CA (1) | CA3151909A1 (ja) |
MX (1) | MX2022002683A (ja) |
WO (1) | WO2021045159A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020343585A1 (en) * | 2019-09-04 | 2022-03-10 | Japan Tobacco Inc. | Chronic kidney disease treatment or prevention method |
EP4364722A1 (en) * | 2021-09-02 | 2024-05-08 | Daewoong Therapeutics Inc. | Pharmaceutical composition for preventing or treating diabetic eye disease comprising sglt-2 inhibitor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011002011A1 (ja) * | 2009-07-01 | 2011-01-06 | キッセイ薬品工業株式会社 | Sglt1阻害薬とdpp-iv阻害薬を組み合わせてなる医薬 |
TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
AR087701A1 (es) | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 | |
CN110066302B (zh) * | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
US10988462B2 (en) * | 2018-04-04 | 2021-04-27 | Japan Tobacco Inc. | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof |
AU2020343585A1 (en) * | 2019-09-04 | 2022-03-10 | Japan Tobacco Inc. | Chronic kidney disease treatment or prevention method |
-
2020
- 2020-09-03 EP EP20860175.7A patent/EP4026564A4/en not_active Withdrawn
- 2020-09-03 CN CN202080076112.9A patent/CN114585387A/zh active Pending
- 2020-09-03 JP JP2021544029A patent/JPWO2021045159A1/ja active Pending
- 2020-09-03 KR KR1020227010592A patent/KR20220056219A/ko unknown
- 2020-09-03 MX MX2022002683A patent/MX2022002683A/es unknown
- 2020-09-03 US US17/639,552 patent/US20230119894A1/en active Pending
- 2020-09-03 EP EP23196223.4A patent/EP4342466A1/en active Pending
- 2020-09-03 WO PCT/JP2020/033463 patent/WO2021045159A1/ja unknown
- 2020-09-03 AU AU2020341926A patent/AU2020341926A1/en active Pending
- 2020-09-03 CA CA3151909A patent/CA3151909A1/en active Pending
- 2020-09-03 BR BR112022003323A patent/BR112022003323A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220056219A (ko) | 2022-05-04 |
US20230119894A1 (en) | 2023-04-20 |
CN114585387A (zh) | 2022-06-03 |
JPWO2021045159A1 (ja) | 2021-03-11 |
EP4342466A1 (en) | 2024-03-27 |
WO2021045159A1 (ja) | 2021-03-11 |
AU2020341926A1 (en) | 2022-03-17 |
MX2022002683A (es) | 2022-04-07 |
BR112022003323A2 (pt) | 2022-05-24 |
EP4026564A4 (en) | 2023-03-15 |
EP4026564A1 (en) | 2022-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2947086B1 (en) | Novel fused pyrimidine compound or salt thereof | |
TWI804933B (zh) | 用作cdk7激酶抑制劑的化合物及其應用 | |
US10988462B2 (en) | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | |
US20220064148A1 (en) | Methyllactam ring compound and pharmaceutical use thereof | |
CA3151909A1 (en) | Therapeutic or prophylactic method for diabetes using combination medicine | |
WO2023078451A1 (zh) | 用作cdk7激酶抑制剂的化合物及其应用 | |
US9238632B2 (en) | 3-cyanoanilinoalkylarylpiperazine derivative and use thereof in preparing drugs | |
US20230210831A1 (en) | Chronic kidney disease treatment or prevention method | |
US20230293539A1 (en) | Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof | |
RU2805312C2 (ru) | Пиразольные соединения, замещенные гетероарилом, и их применение в фармацевтике | |
RU2809634C2 (ru) | Соединение с метиллактамным кольцом и его применение в фармацевтике | |
WO2024092116A1 (en) | Combination of tead inhibitors and egfr inhibitors and uses thereof | |
WO2022092141A1 (ja) | 抗ウイルス活性を有するアミド誘導体 | |
CA3106556A1 (en) | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication |